التفاصيل البيبلوغرافية
| العنوان: |
Significance of Multi-Cancer Genome Profiling Testing for Breast Cancer: A Retrospective Analysis of 3326 Cases from Japan's National Database. |
| المؤلفون: |
Kawabata, Kyoka, Nishikubo, Hinano, Kanei, Saki, Aoyama, Rika, Tsukada, Yuki, Sano, Tomoya, Imanishi, Daiki, Sakuma, Takashi, Maruo, Koji, Yamamoto, Yurie, Wang, Qiang, Zhu, Zhonglin, Fan, Canfeng, Yashiro, Masakazu |
| المصدر: |
Genes; Jun2024, Vol. 15 Issue 6, p792, 10p |
| مصطلحات موضوعية: |
BREAST cancer, DATABASES, FISHER exact test, GENOMES, CANCER genes |
| مصطلحات جغرافية: |
JAPAN |
| مستخلص: |
Background: Breast cancer (BC) has the highest morbidity rate and the second-highest mortality rate of all cancers among women. Recently, multi-cancer genome profiling (multi-CGP) tests have become clinically available. In this study, we aimed to clarify the significance of multi-CGP testing of BC by using the large clinical dataset from The Center for Cancer Genomics and Advanced Therapeutics (C-CAT) profiling database in Japan. Materials and Methods: A total of 3744 BC cases were extracted from the C-CAT database, which enrolled 60,250 patients between June 2019 and October 2023. Of the 3744 BC cases, a total of 3326 cases for which the C-CAT included information on ER, PR, and HER2 status were classified into four subtypes, including TNBC, HR+/HER2−, HR+/HER2+, and HR−/HER2+. Comparisons between groups were performed by the χ2 test or Fisher's exact test using EZR. Kaplan–Meier curves were created using the log-rank test. Results: Of all 3326 cases analyzed, 1114 (33.5%) were TNBC cases, HR+/HER2− accounted for 1787 cases (53.7%), HR+/HER2+ for 260 cases (7.8%), and HR−/HER2+ for 165 cases (5.0%). Genetic abnormalities were most frequently detected in TP53 (58.0%), PIK3CA (35.5%), MYC (18.7%), FGF19 (15.5%), and GATA3 (15.1%) across all BCs. The rate of TMB-High was 12.3%, and the rate of MSI-High was 0.3%, in all BC cases. Therapeutic drugs were proposed for patients with mutations in six genes: PIK3CA, ERBB2, PTEN, FGFR1, ESR1, and AKT1. The prognoses of HR+/HER2− cases were significantly (p = 0.044) better in the treated group than in the untreated group. Conclusions: These findings suggest that cancer gene panel testing is useful for HR+/HER2− cases. [ABSTRACT FROM AUTHOR] |
|
Copyright of Genes is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder